Key issues in the pharmaceutical industry: consequences on R&D

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Expert Opinion on Drug Discovery

• Publication date

  2009-01-01

• Fields of study

  Medicine, Business

• Identifiers
  DOI 10.1517/17460440802604807PMID 23480332
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The cost of biopharmaceutical R&D: is biotech different?

  2007cited by this paper
• Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

  2006cited by this paper
• The Pharmaceutical Research and Manufacturers of America

  2005cited by this paper
• Financial report

  1987cited by this paper
• Financial report

  1984cited by this paper
• The department of health

  1974cited by this paper
• Research and Development in the Pharmaceutical Industry

  1971cited by this paper

• Diffusion, convergence and influence of pharmaceutical innovations: a comparative study of Chinese and U.S. patents

  2018cites this paper
• Early Adoption of Innovative Analytical Approach and Its Impact on Organizational Analytics Maturity and Sustainability: A Longitudinal Study from a U.S. Pharmaceutical Company

  2016cites this paper
• Compound Attrition in Phase II/III

  2015cites this paper
• Network analysis has diverse roles in drug discovery.

  2012cites this paper
• The role of translational bioinformatics in drug discovery.

  2011cites this paper
• REVIEW: Management of gout: beyond allopurinol

  2010cites this paper
• Considering the economic principles of pharmaceutical R&D

  2009influential citation
• Distribution of Second Primary Malignancies Suggests a Bidirectional Effect Between Breast and Endometrial Cancer: A Population-Based Study

  2009cites this paper